Table 1 Patient information and number (n) of surgical samples investigated by molecular methods in this study
Patient | Anatomical site | Age range | Antibiotics | Outcome |
|---|---|---|---|---|
1 (n = 4) | Femur | 70–79 | meropenem, ciprofloxacin and metronidazole (supplemented with clindamycine after sampling). | Survival. |
2 (n = 2) | Crus | 20–29 | meropenem, ciprofloxacin and clindamycine. | Survival. |
3 (n = 1) | Crus | 60–69 | meropenem, ciprofloxacin and clindamycine. (Cefuroxime and Gentamicin before transferral) | Death within 24 h. |
4 (n = 2) | Arm | 60–69 | meropenem, ciprofloxacin and clindamycine. | Survival. |
5 (n = 1) | Inguina | 60–69 | meropenem, ciprofloxacin and clindamycine (suppl. metronidazole after sampling). | Survival. |
6 (n = 1) | Vulva | 60–69 | meropenem, ciprofloxacin and clindamycine. | Death due to disposing disease. |
7 (n = 2) | Neck | 70–79 | PEN and metronidazole. After recurrence: meropenem, metronidazole, linesolid and moxifloxacin. | Survival. |
8 (n = 3) | Shoulder | 60–69 | meropenem, ciprofloxacin and clindamycine. | Survival. |
9 (n = 2) | Shoulder | 40–49 | meropenem, ciprofloxacin and clindamycine. | Survival. |
10 (n = 2) | Arm | 50–59 | meropenem, ciprofloxacin, clindamycine, metronidazole | Survival. |